tiprankstipranks
Trending News
More News >
Dyne Therapeutics (DYN)
NASDAQ:DYN
US Market
Advertisement

Dyne Therapeutics (DYN) AI Stock Analysis

Compare
348 Followers

Top Page

DYN

Dyne Therapeutics

(NASDAQ:DYN)

Rating:43Neutral
Price Target:
Dyne Therapeutics' stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
Positive Factors
Competitive Positioning
Having vHOT as a primary endpoint for an accelerated approval is encouraging for Dyne’s clinical and commercial strategy.
Regulatory Progress
Dyne announced FDA Breakthrough Therapy Designation and updated plan for accelerated approval in myotonic dystrophy type 1.
Treatment Efficacy
DYNE-101 delivers consistent and sustained treatment benefits, showing improvement in myotonia, muscle strength, mobility, and patient-reported outcomes, with consistent safety.
Negative Factors
Endpoint Change Skepticism
The change from splicing to vHOT represents a significant shift that may cause confusion and skepticism among investors.
Investor Concerns
The pivot to vHOT as the primary endpoint, differing from the original CASI-22 plan, could trigger investor concerns due to previous high conviction in CASI-22.

Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)

Dyne Therapeutics Business Overview & Revenue Model

Company DescriptionDyne Therapeutics (DYN) is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company specializes in advancing innovative treatments for rare muscle disorders, leveraging its proprietary FORCE platform to deliver nucleic acid therapeutics precisely to muscle tissue. Dyne's pipeline includes programs aimed at treating conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
How the Company Makes MoneyDyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary
Dyne Therapeutics exhibits characteristics typical of an early-stage biotech firm: significant cash reserves and low leverage support its R&D focus, despite zero revenue and increasing net losses. The strong balance sheet mitigates the risks associated with negative cash flows, contingent on future breakthroughs and commercialization.
Income Statement
15
Very Negative
Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.
Balance Sheet
70
Positive
The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.
Cash Flow
40
Negative
Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-2.46M-3.35M-1.09M-700.00K
EBITDA-315.18M-233.48M-164.75M-148.20M-58.34M
Net Income-317.42M-235.94M-165.24M-149.28M-58.74M
Balance Sheet
Total Assets691.23M165.08M306.32M425.66M353.33M
Cash, Cash Equivalents and Short-Term Investments642.27M123.10M256.01M376.57M345.31M
Total Debt23.99M27.41M30.48M32.64M0.00
Total Liabilities61.40M73.79M53.96M57.47M10.97M
Stockholders Equity629.84M91.29M252.36M368.20M342.37M
Cash Flow
Free Cash Flow-294.75M-188.89M-156.71M-123.18M-47.67M
Operating Cash Flow-292.37M-188.16M-153.65M-119.56M-46.51M
Investing Cash Flow-204.08M83.31M87.20M-137.89M-45.66M
Financing Cash Flow809.89M54.32M37.39M157.82M380.69M

Dyne Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price9.24
Price Trends
50DMA
11.05
Negative
100DMA
10.85
Negative
200DMA
17.41
Negative
Market Momentum
MACD
-0.50
Negative
RSI
44.54
Neutral
STOCH
65.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Neutral. The current price of 9.24 is above the 20-day moving average (MA) of 9.02, below the 50-day MA of 11.05, and below the 200-day MA of 17.41, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 65.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DYN.

Dyne Therapeutics Risk Analysis

Dyne Therapeutics disclosed 80 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Dyne Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥355.44B11.10-2.99%2.49%11.76%-10.16%
61
Neutral
$1.43B-49.41%4.86%10.13%
58
Neutral
$1.33B-105.50%-7.06%-57.17%
57
Neutral
$1.33B-51.85%11070.12%32.07%
48
Neutral
$859.61M-93.70%-25.83%
43
Neutral
$1.31B-64.01%14.93%
36
Underperform
$1.29B-31.30%12.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DYN
Dyne Therapeutics
9.24
-33.46
-78.36%
IOVA
Iovance Biotherapeutics
3.29
-6.14
-65.11%
VRDN
Viridian Therapeutics
17.49
1.15
7.04%
WVE
Wave Life Sciences
8.39
2.09
33.17%
SNDX
Syndax Pharmaceuticals
9.99
-14.64
-59.44%
ELVN
Enliven Therapeutics
21.95
-3.07
-12.27%

Dyne Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Dyne Therapeutics Appoints Erick Lucera as CFO
Positive
Mar 20, 2025

On March 20, 2025, Dyne Therapeutics announced the appointment of Erick Lucera as Chief Financial Officer and Treasurer, effective March 31, 2025. This strategic move follows Lucera’s extensive experience in financial leadership roles within the biotechnology sector, notably at Editas Medicine and AVEO Pharmaceuticals. His appointment coincides with the departure of Richard Scalzo, who will transition to a consulting role. These changes are expected to enhance Dyne Therapeutics’ financial strategy and operational efficiency, potentially impacting its market positioning positively.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025